• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

皮下植入式心律转复除颤器植入术中减少围手术期并发症的方法。

Approaches to Minimizing Periprocedural Complications During Subcutaneous Implantable Cardioverter-defibrillator Placement.

作者信息

Vedachalam Srikanth, Cook Schuyler, Koppert Tanner, Okabe Toshimasa, Weiss Raul, Afzal Muhammad R

机构信息

Division of Cardiovascular Medicine, Wexner Medical Center, Ohio State University Medical Center, Columbus, OH, USA.

Department of Internal Medicine, Adena Regional Medical Center, Chillicothe, OH, USA.

出版信息

J Innov Card Rhythm Manag. 2020 May 15;11(5):4100-4105. doi: 10.19102/icrm.2020.110504. eCollection 2020 May.

DOI:10.19102/icrm.2020.110504
PMID:32461815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7244169/
Abstract

The subcutaneous implantable cardioverter-defibrillator (S-ICD) is the latest option among devices clinically available for the prevention of sudden cardiac death, with experience from previous trials and postmarketing studies supporting the feasibility and safety of this kind of system. The extracardiac positioning of the S-ICD obviates the need for transvenous leads, which translates into lower incidence rates of lead-related complications and systemic infections. This review will highlight the results of pertinent studies related to the perioperative management of S-ICDs and review potential approaches to minimizing the risk of complications such as hematoma at the pulse generator location, unsuccessful defibrillation due to suboptimal S-ICD lead and generator positioning, and postoperative pain. An extensive literature search using PubMed was conducted to identify relevant articles.

摘要

皮下植入式心脏复律除颤器（S-ICD）是临床上可用于预防心脏性猝死的最新设备，先前试验和上市后研究的经验支持了这种系统的可行性和安全性。S-ICD的心外定位避免了经静脉导线的使用，这意味着与导线相关的并发症和全身感染的发生率更低。本综述将重点介绍与S-ICD围手术期管理相关的相关研究结果，并探讨将诸如脉冲发生器部位血肿、S-ICD导线和发生器定位欠佳导致除颤失败以及术后疼痛等并发症风险降至最低的潜在方法。通过使用PubMed进行广泛的文献检索以识别相关文章。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/e80b3535cebf/icrm-11-4100-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/029b2a9bedba/icrm-11-4100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/6cec3b738ded/icrm-11-4100-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/754f2a5bb1a2/icrm-11-4100-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/e80b3535cebf/icrm-11-4100-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/029b2a9bedba/icrm-11-4100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/6cec3b738ded/icrm-11-4100-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/754f2a5bb1a2/icrm-11-4100-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9b5/7244169/e80b3535cebf/icrm-11-4100-g004.jpg

相似文献

1
Approaches to Minimizing Periprocedural Complications During Subcutaneous Implantable Cardioverter-defibrillator Placement.皮下植入式心律转复除颤器植入术中减少围手术期并发症的方法。
J Innov Card Rhythm Manag. 2020 May 15;11(5):4100-4105. doi: 10.19102/icrm.2020.110504. eCollection 2020 May.
2
How to minimize peri-procedural complications during subcutaneous defibrillator implant?如何在皮下植入式除颤器植入过程中尽量减少围手术期并发症？
Expert Rev Cardiovasc Ther. 2020 Jul;18(7):427-434. doi: 10.1080/14779072.2020.1784006. Epub 2020 Jul 2.
3
[Transvenous subcutaneous implantation technique of the cardioverter/defibrillator].[心脏复律除颤器的经静脉皮下植入技术]
Herz. 1994 Oct;19(5):259-77.
4
Development of the subcutaneous implantable cardioverter-defibrillator for reducing sudden cardiac death.用于降低心源性猝死的皮下植入式心律转复除颤器的研发。
Ann N Y Acad Sci. 2014 Nov;1329:1-17. doi: 10.1111/nyas.12550. Epub 2014 Oct 10.
5
Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.皮下与经静脉植入式除颤器治疗的长期临床结果。
J Am Coll Cardiol. 2016 Nov 8;68(19):2047-2055. doi: 10.1016/j.jacc.2016.08.044.
6
Anesthesia care for subcutaneous implantable cardioverter/defibrillator placement: a single-center experience.皮下植入式心脏复律除颤器放置的麻醉管理：单中心经验。
J Clin Anesth. 2016 Jun;31:53-9. doi: 10.1016/j.jclinane.2015.11.009. Epub 2016 Mar 22.
7
Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies.皮下与经静脉植入式心脏除颤器治疗：病例对照研究的荟萃分析。
JACC Clin Electrophysiol. 2017 Dec 26;3(13):1475-1483. doi: 10.1016/j.jacep.2017.07.017. Epub 2017 Sep 27.
8
Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians.皮下植入式心律转复除颤器植入术的麻醉：来自美国一组医生临床经验的观点。
Pacing Clin Electrophysiol. 2018 Jul;41(7):807-816. doi: 10.1111/pace.13364. Epub 2018 Jun 8.
9
The subcutaneous implantable cardioverter-defibrillator in review.皮下植入式心律转复除颤器述评。
Am Heart J. 2019 Nov;217:131-139. doi: 10.1016/j.ahj.2019.08.010. Epub 2019 Aug 17.
10
Safety, Efficacy and Evidence Base for Use of the Subcutaneous Implantable Cardioverter Defibrillator.皮下植入式心律转复除颤器使用的安全性、有效性及循证基础
J Clin Med. 2018 Mar 11;7(3):53. doi: 10.3390/jcm7030053.

本文引用的文献

1
Implantation of subcutaneous defibrillator is feasible and safe with monitored anesthesia care.在麻醉监护下植入皮下除颤器是可行且安全的。
Pacing Clin Electrophysiol. 2019 Dec;42(12):1552-1557. doi: 10.1111/pace.13838. Epub 2019 Nov 18.
2
The subcutaneous implantable cardioverter-defibrillator in review.皮下植入式心律转复除颤器述评。
Am Heart J. 2019 Nov;217:131-139. doi: 10.1016/j.ahj.2019.08.010. Epub 2019 Aug 17.
3
The subcutaneous implantable cardioverter defibrillator in 2019 and beyond.2019 年及以后的皮下植入式心律转复除颤器。
Trends Cardiovasc Med. 2020 Aug;30(6):378-384. doi: 10.1016/j.tcm.2019.09.006. Epub 2019 Oct 1.
4
Subcutaneous ICD: Current standards and future perspective.皮下植入式心律转复除颤器：当前标准与未来展望。
Int J Cardiol Heart Vasc. 2019 Aug 8;24:100409. doi: 10.1016/j.ijcha.2019.100409. eCollection 2019 Sep.
5
Increased risk of hematoma with uninterrupted warfarin in patients undergoing implantation of subcutaneous implantable cardioverter defibrillator.接受皮下植入式心脏复律除颤器植入术的患者，持续使用华法林会增加血肿风险。
Pacing Clin Electrophysiol. 2019 Aug;42(8):1111-1114. doi: 10.1111/pace.13754. Epub 2019 Jul 7.
6
Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing.PRAETORIAN-DFT 试验的原理和设计：皮下植入式心脏复律除颤器植入与不进行除颤测试的前瞻性随机比较试验。
Am Heart J. 2019 Aug;214:167-174. doi: 10.1016/j.ahj.2019.05.002. Epub 2019 May 16.
7
Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results.EMBLEM S-ICD 在低 EF 原发性预防患者中的应用研究（UNTOUCHED）：临床特征和围手术期结果。
Heart Rhythm. 2019 Nov;16(11):1636-1644. doi: 10.1016/j.hrthm.2019.04.048. Epub 2019 May 10.
8
Evolution of extravascular implantable defibrillator technologies.血管外植入式除颤器技术的发展。
Prog Cardiovasc Dis. 2019 May-Jun;62(3):249-255. doi: 10.1016/j.pcad.2019.04.003. Epub 2019 Apr 18.
9
Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success.与高电压阻抗和皮下植入式除颤器心室颤动转复成功相关的因素。
Circ Arrhythm Electrophysiol. 2019 Apr;12(4):e006665. doi: 10.1161/CIRCEP.118.006665.
10
Multicenter Experience of Concomitant Use of Left Ventricular Assist Devices and Subcutaneous Implantable Cardioverter-Defibrillators.左心室辅助装置与皮下植入式心律转复除颤器联合使用的多中心经验
JACC Clin Electrophysiol. 2018 Sep;4(9):1261-1262. doi: 10.1016/j.jacep.2018.05.002.